Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients

Trial Profile

Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Sodium fytate (Primary)
  • Indications Calciphylaxis
  • Focus Therapeutic Use
  • Sponsors Laboratoris Sanifit
  • Most Recent Events

    • 06 Mar 2018 Primary endpoint (Wound Healing:Assessment of lesion score using Bates-Jensen wound assessment tool) has been met, according to a Sanifit media release.
    • 06 Mar 2018 According to a Sanifit media release, full trial results will be presented at a scientific meeting in mid-2018.
    • 06 Mar 2018 According to a Sanifit media release, results for this trial were announced by the company.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top